Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability

Journal of Clinical Pharmacology

Volumn 55, Issue 2, 2015, Pages 189-194

  Glue, Paul ^a   Lockhart, Michelle ^b   Lam, Fred ^c   Hung, Noelyn ^c   Hung, Cheung Tak ^c   Friedhoff, Lawrence ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Zenith Technology   (New Zealand)

^d DemeRx   (United States)

Author keywords

first in man; noribogaine; pharmacodynamics; pharmacokinetics; safety

Indexed keywords

NORIBOGAINE; PLACEBO; GLUCURONIDE; IBOGAINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLEPHARITIS; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; EYE PAIN; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; YOUNG ADULT;

ADULT; DOUBLE-BLIND METHOD; GLUCURONIDES; HEALTHY VOLUNTEERS; HUMANS; IBOGAINE; MALE; YOUNG ADULT;

EID: 84921032883     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.404     Document Type: Article

References (16)

1. Alper KR, Lotsof HS, Kaplan CD,. The ibogaine medical subculture. J Ethnopharmacol. 2008; 115: 9-24.
2. Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V,. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008; 27: 181-194.
3. Lotsof HS, Alexander NE,. Case studies of ibogaine treatment: implications for patient management strategies. Alkaloids Chem Biol. 2001; 56: 293-313.
4. Mash DC, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids Chem Biol. 2001; 56: 155-171.
5. Obach RS, Pablo J, Mash DC,. Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine. Drug Metab Dispos. 1998; 26: 764-768.
6. Baumann MH, Pablo JP, Ali SF, Rothman RB, Mash DC,. Noribogaine (12-hydroxyibogamine): a biologically active metabolite of the antiaddictive drug ibogaine. Ann NY Acad Sci. 2000; 914: 354-368.
7. Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L,. Acute toxicity of ibogaine and noribogaine. Medicina (Kaunas). 2008; 44: 984-988.
8. Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). July 2005. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf. Accessed January 21, 2014.
9. Mitchell LA, MacDonald RA, Brodie EE,. Temperature and the cold pressor test. J Pain. 2004; 5: 233-237.
10. Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL,. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995; 57: PL45-PL50.
11. Koldsø H, Autzen HE, Grouleff J, Schiøtt B,. Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations. PLoS One. 2013; 8: e63635.
12. Pearl SM, Herrick-Davis K, Teitler M, Glick SD,. Radioligand-binding study of noribogaine, a likely metabolite of ibogaine. Brain Res. 1995; 675: 342-344.
13. 35S]GTPgammaS binding. Neuroreport. 1998; 9: 109-114.
14. Antonio T, et al. Effect of iboga alkaloids on μ-opioid receptor-coupled G protein activation. PLoS One. 2013; 8: e77262.
15. Higgins ST, Preston KL, Cone EJ, Henningfield JE, Jaffe JH,. Supersensitivity to naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects. Drug Alcohol Depend. 1992; 30: 13-26.
16. Comer SD, et al. Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. Psychopharmacology (Berl). 2010; 208: 45-55.